### Summary Sheet

**AGENDA NR. 1.13–12.0**

**IS THIS SESSION FOR:**  
- Information [X]  
- Discussion [X]  
- Decision [ ]

**BACKGROUND (INCLUDING PROBLEM STATEMENT):**  
Significant progresses have been achieved in GDF operations in the last 6 months. This was obtained thanks to a team that, in spite of being reduced to just 10 professional staff – including 3 in the regions – has become increasingly motivated.

Since the Coordinating Board approved GDF’s new strategic direction in November 2012, the following key milestones have been reached:

- GDF continued its activities in the procurement and supply of first- and second-line drugs and commodities (including traditional laboratory supply), with a total value of goods procured of more than US $155 million in 2012, and more than US$ 89 million since the beginning of 2013 ([28th GDF Technical Review Committee](#) convened in May 2013).
- Achieved SLD treatment price reductions of up to 27% between 2012 and 2013.
- Multiplied by more than two times the number of quality-assured SLD suppliers and by more than three the number of SLD products in comparison with the 2009 portfolio.
- Continues to strengthen its relationships with suppliers. A new stakeholders meeting was organized in June 2013, with quality management and quality assurance reviews, global forecasts trends shared and assessment of supplier’s capacity conducted.
- Developed a concept paper and engaged discussion on a Global Strategic Stock Pile and Flexible Procurement Fund with the Global Fund and donors, and in the final stage of recruiting a dedicated expert consultancy for the implementation phase.
- Recruited and trained two additional regional support officers (four in total in AFRO, EMRO, EURO, SEARO) to provide technical assistance to countries with new quantification tools and a new country monitoring framework.
- Engaged with several new suppliers for new Group 5 products for inclusion in GDF catalogue. GDF also engaged discussion on supporting rational introduction of new drugs such as *bedaquiline* (Janssen&Janssen), and *delamanid* (Otsuka).
- Commissioned independent studies to support GDF’s new implementation model (providing market data to better monitor global challenge of aligning diagnostics with treatment provision) and bring evidence from countries (in particular on the root causes for TB drugs stock-outs) to serve as a basis for process reengineering.
- Engaged in collaborative studies with partners, such as: with the TB Alliance for a Paediatric TB Market Analysis (UNITAID funding), with CHAI for a SLD Market Analysis (BMGF Funding), and with the Swiss Tropical and Public Health Institute on paediatric forms uptake (USAID funding).

**SUMMARY/OUTLINE OF THE SESSION:**

30 minutes presentation:

1. Update on GDF key achievements and results since the last Board Meeting
2. Update on GDF new strategic framework implementation and data from recent studies
3. Recommendations for the way forward

30 min Q&A/Discussion
Major Discussion Points or Decision Points Requested:

1. Recognize the work done and future actions
2. Underline the need for rapid recruitment of additional staff

Is this a Special Project? (i.e. Should be undertaken for strategic reasons and is currently partially or completely unfunded?)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No X</td>
</tr>
</tbody>
</table>

If so, what funding is already available? 15 M USD from USAID (Oct 2013-Sep 2014)

What is the funding gap? Around 50 M USD one time investment for implementing a Strategic Stock Pile and a Flexible Procurement Fund (under discussion with GF, UNITAID and partners)

Are there HR implications? Yes X No. If so, what?

Staffing of new organigram as per last board meeting decision needs TO BE IMPLEMENTED

Next Steps

Action Required: -

Responsible Agency/Officer: GDF

Timeframe: Immediately